Skip to main content
Clinical Trials/CTRI/2021/11/038270
CTRI/2021/11/038270Not yet recruiting未知

A Prospective Study of Dexamethasone (Ozurdex) Posterior Segment Drug Delivery System in the Treatment of Patients with Cystoid Macular Edema Secondary to Intraocular Vascular Tumors.

V Prasad Eye Institute0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1.Newly diagnosed patients with CME secondary to intraocular vascular tumors
  • 2.Participant is willing and able to give informed consent for participation in the study.
  • 3.Male and Female, aged 10 years or above.
  • 4.BCVA 20/32 to 20/400 inclusive
  • 5.Central subfoveal OCT thickness > 300 microns

Exclusion Criteria

  • 1.Any co-existing ocular disease other than intraocular tumor which might cause macular edema.
  • 2.Intraocular surgery within 3 months
  • 3.History of IOP elevation in response to steroid treatment in either eye.
  • 4.History of glaucoma or optic nerve head change consistent with glaucoma damage, and/or glaucomatous visual field loss in the study eye.

Investigators

Sponsor
V Prasad Eye Institute

Similar Trials